Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Filing Type: Form 8-K (Current Report)
Date of Report: February 7, 2024 (Event Date)
Reporting Period: Specific event date; not a periodic financial report.
The Company, an emerging growth company, entered into a material definitive agreement to commence a rights offering to raise capital for the development of a diagnostics laboratory and clinical trials for a prostate cancer diagnostic metabolite panel.
Key Financial Metrics and Capital Structure
This filing details a proposed capital raise rather than historical financial performance. No revenue, profit, cash flow, or margin data is provided in this document.
- Proposed Capital Raise: Up to $4,500,000 via a Rights Offering.
- Unit Composition: Each Unit consists of one share of SHPH common stock, one warrant (exercise price $2.35), and a percentage equity interest in the subsidiary Shuttle Diagnostics, Inc.
- Anchor Commitment: SRO, LLC (owned by Keith Moore, CEO of Boustead Securities) committed to purchasing $2,250,000 of Units.
- Backstop Provision: SRO, LLC agreed to purchase any remaining unsold Units up to an additional $2,250,000 if the full $4,500,000 is not raised by existing stockholders.
- Pricing: Units will be sold at 90% of the Volume Weighted Average Price (VWAP) of SHPH common stock for the five trading days preceding closing.
- Transaction Costs: Boustead Securities, LLC will receive a commitment fee of $112,500, a commission of 8% of gross proceeds, and $40,000 in diligence expenses.
Material Changes and Agreements
The primary material change is the execution of three agreements on February 7, 2024:
- Securities Purchase Agreement: Establishes the commitment from SRO, LLC and the structure of the Rights Offering.
- Escrow Agreement: Funds raised by SRO, LLC (up to $2,250,000) will be held in escrow with Sutter Securities, Inc. until closing.
- Placement Agent Agreement: Appoints Boustead Securities, LLC as the placement agent on a best-efforts basis.
Condition Precedent: The offering will not close, and escrowed funds will be returned to investors, if the full $4,500,000 is not raised.
Outlook, Risks, and Management Commentary
Use of Proceeds: Funds are intended to develop a diagnostics laboratory for multi-institutional clinical trials to obtain FDA approval for a diagnostic metabolite panel for prostate cancer. The Company also anticipates seeking additional funding via a Small Business Innovation Research (SBIR) grant from the NIH.
Risks and Contingencies:
- Regulatory Timing: The Company must file a Form S-1 registration statement. There is no certainty regarding the timing of filing, SEC comment clearance, or effectiveness.
- Offering Failure: If the full $4,500,000 is not raised, the transaction will not close.
- Forward-Looking Statements: The filing contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the filing status and effectiveness of the Form S-1 registration statement for the Rights Offering.
- Confirm whether the $2,250,000 commitment from SRO, LLC has been deposited into the escrow account with Sutter Securities, Inc.
- Monitor the subscription rate from existing stockholders to determine if the backstop provision is triggered.
- Review the specific terms of the equity interest in Shuttle Diagnostics, Inc. included in the Units.
- Assess the timeline for the proposed clinical trials and the likelihood of securing the anticipated NIH SBIR grant.